Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 16,968 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Normal Skin Clear all
Completed Not applicable Interventional

A Photodynamic Therapy for Treatment of Actinic Keratoses

NCT00558688
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Photodynamic therapy
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 5, 2021 · Synced Jul 22, 2026, 11:05 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome

NCT03100942
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Lanraplenib, Filgotinib, Tirabrutinib, Lanraplenib placebo, Filgotinib placebo, Tirabrutinib placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
34
States / cities
Mesa, Arizona • Phoenix, Arizona • Covina, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Jul 22, 2026, 11:05 AM EDT
Active, not recruiting Phase 1 Interventional

Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers

NCT04459273
View directory record Official record
Conditions
Bladder Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Hepatocellular Carcinoma, Malignant Adrenal Gland Neoplasm, Malignant Brain Neoplasm, Malignant Pleural Neoplasm, Malignant Skin Neoplasm, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Malignant Thymus Neoplasm, Neuroendocrine Neoplasm, Thyroid Gland Carcinoma, Urothelial Carcinoma, Cancer of Unknown Primary Site
Interventions
Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography, 18F-FDG
Procedure · Drug · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 22, 2026, 11:05 AM EDT
Completed No phase listed Observational

Developing a New Questionnaire About Patient Expectations of Breast Conserving Therapy

NCT02753673
View directory record Official record
Conditions
Breast Cancer
Interventions
qualitative interviews with patients, questionnaires
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Jul 22, 2026, 11:05 AM EDT
Completed Phase 1 Interventional

Study of Ruxolitinib Cream in Children With Atopic Dermatitis

NCT05034822
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
2 Years to 11 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
15
States / cities
Gilbert, Arizona • Hot Springs, Arkansas • Anaheim, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Jul 22, 2026, 11:05 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

A Comparison of TCC-EZ Using Human Amnion Allograft vs TCC-EZ and Standard Wound Care in Treating Diabetic Foot Ulcers.

NCT02344329
View directory record Official record
Conditions
Diabetic Foot Ulcers, Diabetes
Interventions
Topical wound dressing, Human Amnion Allograft, usual wound care
Device · Biological · Other
Lead sponsor
University of North Dakota
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Jul 22, 2026, 11:05 AM EDT
Completed Phase 3 Interventional

Incision and Drainage Versus Needle Aspiration in Soft Tissue Abscesses

NCT01085929
View directory record Official record
Conditions
Abscess, Cellulitis
Interventions
Incision and Drainage, Ultrasound Guided Aspiration
Procedure
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2010 · Synced Jul 22, 2026, 11:05 AM EDT
Completed No phase listed Observational Results available

A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis

NCT06418529
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tofacitinib, tumor necrosis factor inhibitors (TNFi), abatacept, tocilizumab or sarilumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
21,340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 22, 2026, 11:05 AM EDT
Completed Early Phase 1 Interventional

Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy

NCT02517502
View directory record Official record
Conditions
Cognitive Dysfunction
Interventions
DHA, Placebo
Drug
Lead sponsor
Carol Fabian, MD
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Decatur, Illinois • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2022 · Synced Jul 22, 2026, 11:05 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

NCT02711137
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Jul 22, 2026, 11:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Single Cell Genomics of Psoriatic Skin

NCT02929745
View directory record Official record
Conditions
Psoriasis
Interventions
Skin biopsy, Blood draw
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Jul 22, 2026, 11:05 AM EDT
Recruiting Not applicable Interventional

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

NCT02945579
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions
Undergo EBRT, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Partial Breast Irradiation
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
30 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
8
States / cities
Gilbert, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 22, 2026, 11:05 AM EDT
Completed Phase 3 Interventional Results available

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)

NCT04202679
View directory record Official record
Conditions
Neurodermatitis
Interventions
Dupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Fort Smith, Arkansas • Sacramento, California • Pembroke Pines, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Jul 22, 2026, 11:05 AM EDT
Completed Not applicable Interventional

A Research Study for Latina Women After Breast Cancer Treatment

NCT03645005
View directory record Official record
Conditions
Cancer-related Problem/Condition, Quality of Life, Stress, Emotional
Interventions
"My Guide" (psychoeducation & self-management program), "My Health" (health education program)
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
21 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Jul 22, 2026, 11:05 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment

NCT02253251
View directory record Official record
Conditions
Cancer
Interventions
KRAS-variant and microRNA binding site mutation testing
Genetic
Lead sponsor
MiraKind
Other
Eligibility
18 Years and older
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2035
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Jul 22, 2026, 11:05 AM EDT
Recruiting No phase listed Observational

Novel Body Composition Measurements in Association With Outcomes of Breast Reconstruction Reconstruction

NCT07546331
View directory record Official record
Conditions
Breast Carcinoma, Breast Cancer
Interventions
Measurement of Body Composition, Chart Review
Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 22, 2026, 11:05 AM EDT
Terminated Not applicable Interventional

Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases

NCT03937856
View directory record Official record
Conditions
Inflammatory Arthritis, Scleroderma, Myositis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Vasculitis
Interventions
Calm- Mindfulness Meditation smartphone application
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Jul 22, 2026, 11:05 AM EDT
Terminated Phase 3 Interventional

Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis

NCT03398837
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
Lenabasum 5 mg, Lenabasum 20 mg, Placebo oral capsule
Drug · Other
Lead sponsor
Corbus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
27
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Jul 22, 2026, 11:05 AM EDT
Recruiting Not applicable Interventional

CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer

NCT06915168
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Informational Intervention, Survey Administration
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 22, 2026, 11:05 AM EDT
Completed Not applicable Interventional Results available

Cosmetic Result/Toxicity in Post-Mastectomy Immediate Reconstruction Expander+RT

NCT01664091
View directory record Official record
Conditions
Breast Cancer
Interventions
post-mastectomy radiation therapy (PMRT), tissue expander (TE), acellular dermal matrix (ADM)
Radiation · Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 25, 2019 · Synced Jul 22, 2026, 11:05 AM EDT
Recruiting Phase 1 Interventional

Q702 for the Treatment of Patients With Hematologic Malignancies

NCT06712810
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma, Malignant Histiocytosis, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelofibrosis, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Erdheim-Chester Disease, Refractory Follicular Lymphoma, Refractory Langerhans Cell Histiocytosis, Refractory Lymphoplasmacytic Lymphoma, Refractory Myelodysplastic Syndrome, Refractory Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Refractory Waldenstrom Macroglobulinemia, Rosai-Dorfman-Destombes Disease, Primary Central Nervous System Lymphoma, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Erdheim-Chester Disease, Recurrent Fibroblastic Reticular Cell Sarcoma, Recurrent Histiocytic Sarcoma, Recurrent Interdigitating Dendritic Cell Sarcoma, Recurrent Rosai-Dorfman-Destombes Disease, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Fibroblastic Reticular Cell Sarcoma, Refractory Histiocytic Sarcoma, Refractory Interdigitating Dendritic Cell Sarcoma, Refractory Rosai-Dorfman-Destombes Disease
Interventions
Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Survey Administration
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Jul 22, 2026, 11:05 AM EDT
Completed Phase 1 Interventional

Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

NCT04703920
View directory record Official record
Conditions
Metastatic Breast Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Ovarian Carcinoma, Metastic or Unresectable Pancreatic Adenocarcinoma
Interventions
Talazoparib, Belinostat
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Jul 22, 2026, 11:05 AM EDT
Completed Not applicable Interventional

Use of a Radiolucent Pad to Reduce Mammography Among African Americans

NCT00594282
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiolucent cushion
Device
Lead sponsor
University of Kansas
Other
Eligibility
40 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2008 · Synced Jul 22, 2026, 11:05 AM EDT
Completed No phase listed Observational

Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy

NCT03438279
View directory record Official record
Conditions
Melanoma
Interventions
Non-Interventional
Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced Jul 22, 2026, 11:05 AM EDT